安旭生物(688075) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for the third quarter was ¥95,539,646.52, a decrease of 38.41% compared to the same period last year[4] - Total profit for the quarter was ¥2,745,852.23, down 86.30% year-over-year[4] - Net profit attributable to shareholders was ¥5,052,702.96, reflecting a decline of 75.31% compared to the previous year[4] - The basic earnings per share for the quarter was ¥0.04, a decrease of 75.00% year-over-year[4] - Net profit for the first three quarters of 2025 was CNY 64,308,065.31, down 52.7% from CNY 135,748,290.64 in the same period of 2024[19] - Basic and diluted earnings per share for the first three quarters of 2025 were both CNY 0.51, compared to CNY 1.07 in the same period of 2024[20] - The company’s total comprehensive income for the first three quarters of 2025 was CNY 60,620,699.74, down from CNY 143,387,343.88 in the same period of 2024[19] Cash Flow and Assets - The company reported a net cash flow from operating activities of ¥1,182,438.02, a significant drop of 95.13% year-to-date[4] - Cash and cash equivalents decreased to RMB 196,861,400.08 from RMB 467,922,697.94, representing a decline of approximately 58%[15] - Total current assets were RMB 4,629,730,923.04, down from RMB 4,769,982,927.28, indicating a decrease of about 3%[15] - Cash flow from operating activities generated a net amount of CNY 1,182,438.02, significantly lower than CNY 24,260,942.83 in the first three quarters of 2024[20] - The total cash flow from operating activities was not detailed, but the overall cash and cash equivalents decreased by 276,540,863.67 during the period[21] - Cash and cash equivalents at the end of the period amounted to 181,742,814.48, slightly up from 181,017,444.31 in the previous period[21] Liabilities and Equity - The company reported a total liability of CNY 484,843,392.64, down from CNY 569,523,608.49 in the previous year[17] - Total equity attributable to shareholders decreased to CNY 5,162,604,172.76 from CNY 5,203,599,188.59[17] - Total liabilities included accounts payable of RMB 278,902,535.40, down from RMB 327,672,505.40, a decrease of about 15%[16] - The company reported a significant reduction in employee compensation liabilities, decreasing to RMB 11,374,288.37 from RMB 19,864,855.74, a decline of approximately 43%[16] Operational Costs and Expenses - Research and development expenses totaled ¥16,292,479.86, a decrease of 40.59% compared to the same period last year[5] - Total operating costs increased slightly to CNY 392,903,928.66 from CNY 390,136,270.04, with operating costs specifically decreasing from CNY 233,453,244.12 to CNY 192,489,887.23, a reduction of 17.5%[18] - Other income decreased to CNY 5,594,830.22 from CNY 14,581,342.75, indicating a decline in additional revenue sources[18] Shareholder Information - The company has no pledged or frozen shares among its top shareholders, indicating a stable ownership structure[12] - The largest shareholder, Hangzhou Aixi Holdings, holds 26.87% of the shares, while the second-largest shareholder, Ling Shisheng, holds 25.12%[12] - The company has not reported any significant changes in shareholder relationships or actions regarding stock lending[13] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[22] - The company attributed the decline in performance primarily to the impact of U.S. tariffs causing customers to delay orders and foreign exchange losses[9]